Based on the 89bio Inc stock forecast from 3 analysts, the average analyst target price for 89bio Inc is USD 28.40 over the next 12 months. 89bio Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of 89bio Inc is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, 89bio Inc’s stock price was USD 9.21. 89bio Inc’s stock price has changed by -18.50% over the past week, +29.17% over the past month and -16.50% over the last year.
No recent analyst target price found for 89bio Inc
No recent average analyst rating found for 89bio Inc
Company Overview 89bio Inc
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California. Read Less
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for ...Read More
Frequently Asked Questions About 89bio Inc (ETNB) Stock
Based on ratings from 3 analysts 89bio Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 5 buy, sell and hold ratings.
Unfortunately we do not have enough data on ETNB's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for ETNB is USD 28.40 over the next 12 months. The maximum analyst target price is USD 38 while the minimum anlayst target price is USD 17.
ETNB stock's Price/Earning ratio is -99,999.99.
Our analysis grades ETNB stock's Price / Earning ratio at A+. This means that ETNB stock's Price/Earning ratio is above 2.000000000000002% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ETNB may be undervalued for its sector.
The last closing price of ETNB's stock was USD 9.21.
The most recent market capitalization for ETNB is USD 1.03B.
Based on targets from 3 analysts, the average taret price for ETNB is projected at USD 28.40 over the next 12 months.
This means that ETNB's stock price may go up by +208.36% over the next 12 months.
We can't find any ETFs which contains 89bio Inc's stock.
As per our most recent records 89bio Inc has 70 Employees.
89bio Inc's registered address is 142 Sansome Street, San Francisco, CA, United States, 94104.
You can get more information about it from 89bio Inc's website at https://www.89bio.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Negative earnings
The company had negative total earnings in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About 89bio Inc (ETNB) Stock
Based on ratings from 3 analysts 89bio Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 5 buy, sell and hold ratings.
Unfortunately we do not have enough data on ETNB's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for ETNB is USD 28.40 over the next 12 months. The maximum analyst target price is USD 38 while the minimum anlayst target price is USD 17.
ETNB stock's Price/Earning ratio is -99,999.99.
Our analysis grades ETNB stock's Price / Earning ratio at A+. This means that ETNB stock's Price/Earning ratio is above 2.000000000000002% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ETNB may be undervalued for its sector.
The last closing price of ETNB's stock was USD 9.21.
The most recent market capitalization for ETNB is USD 1.03B.
Based on targets from 3 analysts, the average taret price for ETNB is projected at USD 28.40 over the next 12 months.
This means that ETNB's stock price may go up by +208.36% over the next 12 months.
We can't find any ETFs which contains 89bio Inc's stock.
As per our most recent records 89bio Inc has 70 Employees.
89bio Inc's registered address is 142 Sansome Street, San Francisco, CA, United States, 94104.
You can get more information about it from 89bio Inc's website at https://www.89bio.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ETNB !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
